Ion Beam Applications SA IBAB

IBA to offer QUANTM® Irradiation System solid-target technology to cyclotron users worldwide, scaling local production of radiometals for theranostics Louvain-la-Neuve, Belgium – October 1st, 2026, 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions today announced a new agreement with ARTMS Inc. (a Telix company) for IBA to distribute ARTMS’s proprietary solid‑target

Louvain-La-Neuve, Belgium, September 29, 2026 at 7 a.m. CEST – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with the Istituti Fisioterapici Ospitalieri & Istituto Nazionale Tumori Regina Elena (IFO), to provide a turnkey proton therapy solution in Rome, Italy. The center will be the first gantry-based proton therapy

New expert-led services platform will help healthcare providers develop, implement, and optimize proton therapy and advanced radiation oncology programs across the full care delivery lifecycle PHILADELPHIA, Pa., and LOUVAIN-LA-NEUVE, Belgium, 28 September 2026, 7 a.m. CEST — Penn Medicine and IBA today announced the formation of Noventra Oncology Alliance, a new joint venture designed to help healthcare providers successfully develop, implement, and optimize proton therapy and advanced radiation

More than 25 imaging and machine QA tests in one setup. Louvain-la-Neuve, Belgium, 27 September 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a global provider of dosimetry and quality assurance (QA) solutions, today announces the launch of the QUASAR®1 Penta-Guide Performance Phantom. Designed for modern radiotherapy workflows, the new phantom enables more than 25 imaging and machine QA tests to be performed in a single setup. By cons

Louvain-la-Neuve, Belgium, 25 September 2026, 7 a.m. CEST – IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, today announces it will coordinate the LIFEDESTINY, a new European LIFE project dedicated to tackling one of today’s most persistent environmental challenges: PFAS contamination. The consortium will demonstrate a more sustainable, scalable and cost-effective approach to permanently degrading PFAS across different contaminated matrices. PFAS, o

(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, September 8, 2026 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on August

Louvain-la-Neuve, Belgium, 2 September 2026, 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces its participation in PFAROS, a new European research and innovation initiative launched to address environmental emissions and exposure concerns related to per- and polyfluoroalkyl substances (PFAS) in the pharmaceutical and medical sectors. As part of the project, IBA will co-lead the work on end-of-life and waste-management techn

Louvain-la-Neuve, Belgium, 27 August 2026, 7 a.m. - IBA (Ion Beam Applications S.A.), today announces its consolidated results for the first half of 2026, with performance on track with FY 2026 guidance and continued progress towards its profitability improvement trajectory. The period was marked by strong commercial momentum, notably in Proton Therapy and RadioPharma Solutions, as well as the strengthening of IBA’s leadership team and Board to support the Group’s growth and execution of its str

HY26 results webcast to take place on Thursday, 27 August 2026 at 3 p.m. CEST Louvain-la-Neuve, Belgium, 6 August 2026, 7 a.m. - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the half year 2026 on Thursday, 27 August 2026 at 7 a.m. CEST. Conference Call Information IBA’s management team will host a conference call and webcast conducted in English to present the half year results,

July 14th, 2026 Publication made under article 15 of the law of May 2, 2007 relating to the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market and containing various provisions (Belgian Gazette 12.VI.2007) (hereinafter, the “Law”). Under this provision: « [...] the issuer publishes the total capital, the total number of securities conferring the right to vote and voting rights, as well as, by category, the number of securities conferring the right

Louvain-La-Neuve, Belgium, June 30, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, announces today the entering into effect of a contract with Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto), for the installation of two Proteus®ONE1 compact proton therapy solutions at the IPO-Porto facilities in Porto, Portugal. The two Proteus®ONE system

Louvain-La-Neuve, Belgium, June 25, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with the Fundação Severino Sombra (FUSVE), a non-profit philanthropic healthcare and educational institution responsible for the University of Vassouras and Hospital Mário Kroeff, for the purchase of a Proteus®ONE1 system. The ini

Louvain-la-Neuve, Belgium, 17 June 2026 - At its Board meeting held yesterday in Louvain-la-Neuve, IBA (Ion Beam Applications S.A., EURONEXT) welcomed two new Board members, acknowledged the departure of outgoing directors, and announced the payment of €0.25 dividend per share on July 1st. New directors with international scientific and business experienceThe Board thanks the two distinguished directors who are leaving and welcomes two new members whose international scientific and business expe

Olivier Legrain, CEO of IBA, is appointed Vice-Chairman of the IBA Board of Directors and Henri de Romrée, Deputy CEO, assumes strategic and operational responsibility for all Group activities. Catherine Vandenborre is appointed Chief Ventures & Corporate Officer. Louvain-la-Neuve, Belgium, 17 June 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces a new step in the deployment of its leadership team to prepare for the future. Henri d

Louvain-la-Neuve, Belgium, June 8th, 2026 – 6 PM CEST – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026. Under this program, IBA has requested a financial intermediary to repurchase up to 400,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until Septembe

Louvain-La-Neuve, Belgium, June 08, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces the signing of a contract with Duke University Health System for the installation of two Proteus®ONE1 compact proton therapy solutions at the Duke Proton Center in Durham, NC, USA. The two Proteus®ONE systems will be installed side by side in a configurat